March 24, 2021
Everlywell, a leader in the at-home diagnostic testing space, has acquired PWNHealth and its subsidiary Home Access Health to form a new parent company called Everly Health.
PWNHealth and Home Access Health both have self-collected lab test services, and by combining the companies, Everly Health will support more than 20 million people annually in all 50 U.S. states, Canada and Puerto Rico,...
March 11, 2021
Today there are still a lot of questions around getting the workforce back into the office, clinic or manufacturing site. Digital health company Truepill is looking to address this issue by teaming up with the Health Transformation Alliance to offer Truepill's new employer-focused suite of COVID-19-focused diagnostics and digital tools to the former's members.
Truepill's new program will...
March 5, 2021
The FDA has issued its first emergency use authorization for a COVID-19 molecular diagnostic test that does not require a prescription and can be used at home.
Developed by Cue Health, the Cue COVID-19 Test for Home and Over the Counter Use was first authorized for point-of-care use last June.
It uses a nasal swab sample collected from the lower nose to detect the presence of SARS-CoV-2 RNA, and...
December 3, 2020
Everlywell, a digital consumer platform for ordering and viewing lab tests from home, has closed an oversubscribed $175 million Series D funding round, the Austin, Texas-based company announced this morning.
The raise brought in a slew of new investors hailing from BlackRock, the Chernin Group, Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures and Portfolia. It also saw...
November 24, 2020
UK-based independent technology and product development company, the Technology Partnership Plc (TTP), is seeking partnerships for CoTest, a new pooled screening technology for COVID-19.
The technology can be used in any location, to screen up to 40 people at once for the virus, with results available in 30 minutes.
WHY IT MATTERS
CoTest enables screening of large groups, such as school classes...
November 18, 2020
Yesterday afternoon, the U.S. FDA issued an Emergency Use Authorization (EUA) to a COVID-19 molecular diagnostic test that provides individuals with a result within 30 minutes, in the comfort of their home.
As opposed to currently available at-home testing products, which have patients self-collect a nasal swab sample and ship it for processing in a lab, the Lucira COVID-19 All-in-One Test Kit...